Form 4: Ocular Therapeutix Executive Transfers Shares

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc., transferred 50,092 shares of common stock to his spouse on June 16, 2026.

Summary

• Pravin Dugel, a key executive and director at Ocular Therapeutix, Inc. (OCUL), reported a transaction on June 16, 2026.
• The transaction involved the transfer of 50,092 shares of common stock to his spouse.
• This transfer was made for no monetary consideration.
• Following this transaction, Mr. Dugel's beneficial ownership of common stock is reported as 2,547,078 shares, held directly.
• Additionally, 50,092 shares are held indirectly by his spouse, and 694,811 shares are held by the 2024 Irrevocable Trust of Pravin Dugel.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine share transfer by an executive, which does not inherently signal positive or negative performance or strategic shifts for the company.

Positives

• The transfer of shares to a spouse can be part of estate planning or personal financial management, which is a normal activity for executives.
• The executive continues to hold a significant number of shares directly (2,547,078) and indirectly through a trust (694,811), indicating continued substantial investment in the company.

Negatives

• The filing reports a transfer of shares, which, while not necessarily negative, represents a change in the direct beneficial ownership of a portion of the executive's holdings.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions and are essential for monitoring executive and director activity within publicly traded companies. Such filings provide transparency regarding changes in beneficial ownership.

Related Party Transactions

• Transfer of 50,092 shares of common stock from Pravin Dugel to his spouse for no consideration.

Stakeholder Impact

• Shareholders: The transfer does not change the total number of outstanding shares but shifts direct beneficial ownership. The continued significant holdings by the executive and trust suggest ongoing commitment.
• Management: Reflects standard personal financial planning activities of key personnel.

Key Dates

Keywords

Form 4, SEC Filing, Ocular Therapeutix, OCUL, Pravin Dugel, Stock Transfer, Beneficial Ownership, Insider Transaction, Common Stock